Results 181 to 190 of about 209,309 (280)

Ancient Schwannoma in the Nasal Cavity—A Rare Case Report With Brief Literature Review

Eye &ENT Research, Volume 3, Issue 3, Page 179-185, September 2026.
Shikhar Chohan, Annmy Jose, Sufian Zaheer   +2 more
wiley   +1 more source

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, Volume 81, Issue 9, Page 3171-3184, September 2026.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis. [PDF]

Front Pharmacol
Khalifa MA, Ahmed Shimal A, Mahmoud MH, Roumi Jamal B, Atef P, Ali Ahmed MS, Khalil I, Alatise MB, Dway A, Irhayyif SR.   +9 more
europepmc   +1 more source

Efferocytosis failure in chronic rhinosinusitis with nasal polyps: receptor-level mechanisms of unresolved type 2 inflammation. [PDF]

Front Immunol
Tang S, Liu H.
europepmc   +1 more source

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

Allergy, Volume 81, Issue 9, Page 3345-3360, September 2026.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, Sara C. Hamon, Jennifer Maloney, Jamie M. Orengo, Zhen Chen, Stephanie Amato Ricci, Bolanle Akinlade, Aris Baras, Gary Herman, Brandy L. Bennett, George D. Yancopoulos   +19 more
wiley   +1 more source

Dose tapering and treatment de-escalation of biologic therapies in chronic rhinosinusitis with nasal polyps: a narrative review. [PDF]

Front Surg
AlSharhan SS, Aljubran HJ.
europepmc   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, Volume 81, Issue 9, Page 3107-3129, September 2026.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

Allergy, Volume 81, Issue 9, Page 3261-3272, September 2026.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler, Sally E. Wenzel, Steve D. Groshong, Mario Castro, Ian D. Pavord, Klaus F. Rabe, Elizabeth Laws, Alexandre Jagerschmidt, Kaitlyn Gayvert, Sivan Harel, Jennifer D. Hamilton, Nikhil Amin, Lu Zhang, Heming Xing, Anissa Elfakir, Bema Coulibaly, Souâd Naimi, Sara Hamon, Paul J. Rowe, Frank Nestle, Danen M. Cunoosamy, Emanuele de Rinaldis, Leda P. Mannent   +22 more
wiley   +1 more source

Extension of Dupilumab Injection Intervals in Chronic Rhinosinusitis with Nasal Polyps: A Real-World Study. [PDF]

Pharmaceuticals (Basel)
Habenbacher M, Moser U, Lang A, Abaira A, Pock J, Lampl T, Andrianakis A.   +6 more
europepmc   +1 more source